Hologic Deserves To Trade At A Premium, Says Bank Of America

Loading...
Loading...

Bank of America reiterated a Buy on Hologic, Inc. HOLX, just one day after the company announced the FDA has approved the use of its Procleix Zika Virus Assay to screen the U.S. blood supply for the Zika virus.

U.S. Blood centers in southern parts of the country that are susceptible to the Zika virus will use the Procleix Zika virus assay to screen donated blood for the virus. Testing could be expanding throughout the US if the virus spreads.

Bank of America analysts report, "Zika blood screening test release is a step in the right direction." While the FDA hasn't mandated a Zika screening yet, it could do so as early as this summer.

Bank of America’s bull case suggests the new Zika screening is a 20-25 million sales opportunity for the company. Hologic is rated a Buy given “positive fundamentals and a very reasonable valuation."

Hologic was down 0.7 percent at $33.88.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorAnalyst RatingsBank of America
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...